Related references
Note: Only part of the references are listed.Myeloid differentiation primary response 88 mutations in a distinct type of cutaneous marginal-zone lymphoma with a nonclasss-witched immunoglobulin M immunophenotype
M. Wobser et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing
Steven H. Swerdlow et al.
VIRCHOWS ARCHIV (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies
Andi K. Cani et al.
MODERN PATHOLOGY (2016)
Dermatological manifestations of monoclonal gammopathies: Contribution of cutaneous histopathology
Caroline Lacoste et al.
ANNALES DE PATHOLOGIE (2015)
Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia
Giovanni Insuasti-Beltran et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2015)
MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity
Janine Schmidt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenstrom's Macroglobulinemia
O. Landgren et al.
LEUKEMIA (2014)
Detection of MYD88 L265P Mutation by Real-Time Allele-Specific Oligonucleotide Polymerase Chain Reaction
Cristina Jimenez et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2014)
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
Guang Yang et al.
BLOOD (2013)
A new era for Waldenstrom macroglobulinemia: MYD88 L265P
Steven P. Treon et al.
BLOOD (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia
C. Jimenez et al.
LEUKEMIA (2013)
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
W. Kraan et al.
BLOOD CANCER JOURNAL (2013)
MYD88 L265P Somatic Mutation in IgM MGUS
NEW ENGLAND JOURNAL OF MEDICINE (2012)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cutaneous manifestations of paraproteinemia and their mechanisms
Dan Lipsker et al.
PRESSE MEDICALE (2007)
Cutaneous infiltration with Waldenstrom macroglobulinemia
T. Yokote et al.
LEUKEMIA RESEARCH (2006)
Cutaneous Waldenstrom's macroglobulinemia with deck-chair sign treated with cyclophosphamide
J Autier et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Cutaneous lymphoplasmacytoid lymphoma (immunocytoma) with Waldenstrom's macroglobulinemia mimicking rosacea
JH Colvin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
Cutaneous Waldenstrom's macroglobulinaemia
I Chan et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2003)
Cutaneous Waldenstrom's macroglobulinemia: Report of a case and overview of the spectrum of cutaneous disease
LF Libow et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2001)
Share Paper
